PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-CD38 ANTIBODY AND A HYALURONIDASE
Patent Information
- Application Number
- ARP20250100327
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-11-03
- Filing Date
- 2025-02-06
- Publication Date
- 2026-07-22
Claims
The present invention relates to subcutaneous formulations of anti-CD38 antibodies and their uses.
1. A pharmaceutical composition characterized in that it comprises: a) an anti-CD38 antibody comprising a heavy chain variable region (HV) of SEQ ID No. 4 and a light chain variable region (LV) of SEQ ID No. 5; and b) recombinant hyaluronidase rHuPH20, wherein the pharmaceutical composition comprises 1,800 mg of the anti-CD38 antibody and has a hyaluronidase enzyme activity of 30,000 U.
7. A pharmaceutical composition characterized in that it comprises daratumumab, histidine, sorbitol and a surfactant, wherein the turbidity of the pharmaceutical composition is approximately 6 Nephelometric Turbidity Units (NTU) or less after storage for 1 month at 25°C and 60% relative humidity.